- Home
- GSIW vs GNPX Comparison
GSIW vs GNPX Comparison
Compare GSIW & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- GNPX
- Stock Information
- Founded
- GSIW 2016
- GNPX 2009
- Country
- GSIW Hong Kong
- GNPX United States
- Employees
- GSIW N/A
- GNPX N/A
- Industry
- GSIW
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- GNPX Health Care
- Exchange
- GSIW Nasdaq
- GNPX Nasdaq
- Market Cap
- GSIW 8.1M
- GNPX 9.4M
- IPO Year
- GSIW 2023
- GNPX 2018
- Fundamental
- Price
- GSIW $0.18
- GNPX $0.20
- Analyst Decision
- GSIW
- GNPX
- Analyst Count
- GSIW 0
- GNPX 0
- Target Price
- GSIW N/A
- GNPX N/A
- AVG Volume (30 Days)
- GSIW 13.8M
- GNPX 4.2M
- Earning Date
- GSIW 01-01-0001
- GNPX 11-12-2025
- Dividend Yield
- GSIW N/A
- GNPX N/A
- EPS Growth
- GSIW N/A
- GNPX N/A
- EPS
- GSIW N/A
- GNPX N/A
- Revenue
- GSIW $5,368,221.00
- GNPX N/A
- Revenue This Year
- GSIW N/A
- GNPX N/A
- Revenue Next Year
- GSIW N/A
- GNPX N/A
- P/E Ratio
- GSIW N/A
- GNPX N/A
- Revenue Growth
- GSIW 283.23
- GNPX N/A
- 52 Week Low
- GSIW $0.09
- GNPX $0.14
- 52 Week High
- GSIW $2.59
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- GSIW 54.81
- GNPX 49.27
- Support Level
- GSIW $0.14
- GNPX $0.16
- Resistance Level
- GSIW $0.16
- GNPX $0.22
- Average True Range (ATR)
- GSIW 0.02
- GNPX 0.02
- MACD
- GSIW 0.01
- GNPX -0.00
- Stochastic Oscillator
- GSIW 91.84
- GNPX 44.32
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.